[ad_1]
The EMA has approved Aimovig of Norvartis (erenumab), making it the first European treatment specifically designed to prevent migraine .
The drug works by blocking the calcitonin gene. related peptide receptor (CGRP), thought to be involved in the transmission of pain signals associated with migraine.
Migraine is a complex and debilitating neurological condition that affects each individual differently. It is estimated that more than 610,000 people in the UK suffer from chronic migraine, the 2010 Equality Act equating migraine with a disability if the disease had a long-term impact on work or daily activities [19659005]. 9.7 billion pounds a year are lost in the UK solely because of migraine through direct costs (patient treatment) and indirect (lost productivity), but migraine remains the least funded by the state of all neurological diseases.
showed a reduction in the average number of monthly migraine days in episodic and chronic migraine patients, including those who tried existing treatment options, "said Professor Zameel Cader, consultant neurologist at the NHS Foundation Trust and at the Oxford Headache Center. . "Today's news represents a new approach for the clinical community in our ability to treat those who suffer the most from migraine."
First Decisions on Eenumab for the Prevention of Migraine The headache of the National Institute of Excellence in Health Care (NICE) and the Scottish Medicine Consortium (SMC) is expected in 2019. Novartis says working closely with all stakeholders to ensure eligible patients can begin to benefit from this treatment as soon as possible. A tailored patient support program and a range of resources are also being developed to provide support to patients and health professionals.
Source link
